IP Library Granted Patent US 8,435,491
Granted Patent B2
US 8,435,491 · App. 12/779,374 · Granted May 7, 2013

Quantification method for remaining liver function and novel liver receptor imaging agent

Inventors: Mei-Hui Wang (Taoyuan County, TW); Wuu-Jyh Lin (Taoyuan County, TW); Chuan-Yi Chien (Taoyuan County, TW); Hung-Man Yu (Taoyuan County, TW); Reiko Takasaka Lee (Baltimore, MD); Yuan-Chuan Lee (Baltimore, MD)
Assignee: Institute of Nuclear Energy Research Atomic Energy Council, Executive Yuan
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,435,491
App. No.
12/779,374
Granted
May 7, 2013
Kind
B2
Abstract

A test indicator for quantifying remaining liver function is provided. A novel liver receptor imaging agent with liver targeting property is utilized to develop a method for quantifying remaining liver function to serve as test indicator for judging the liver failure outcome in clinic, particularly for judging the necessity of liver transplantation for patients with liver failure or liver disease. The radioactivity uptake of the test indicator was negatively correlated with the extent of liver reserve. The cutoff value of liver reserve for liver transplantation is also disclosed.

Claims (6)

1. A quantification method for remaining liver function on mice, using in vivo molecular imaging with SPECT/CT, comprising:

(a) intravenously injecting a radiation dose of 200 nCi/g of a liver receptor imaging agent ln-111 Hexa-Lactoside;

(b) measuring the radioactivity per square unit of liver with a SPECT medical imaging instrument at a specific fixed time;

(c) taking the radioactivity absorbed by liver in a normal group as 100% of remaining liver function; and

(d) determining the relative remaining liver function by comparing the radioactivity absorbed by liver in each disease group with that in the normal group.

2. The method according to claim 1 , wherein when the remaining liver function is lower than 25%, a liver transplantation is necessary.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2010
From: WANG, MEI-HUI; LIN, WUU-JYH; CHIEN, CHUAN-YI; YU, HUNG-MAN; LEE, REIKO TAKASAKA; LEE, YUAN-CHUAN
To: INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN
Reel/Frame 024381/0231 →
Priority Claims (1)
TW 98136146 A · Oct 26, 2009 · national
Continuity (1)
Related Publication 20110097265A1 · Apr 28, 2011